Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
PFE — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

2.84

Margin Of Safety %

18

Put/Call OI Ratio

0.82

EPS Next Q Diff

-0.06

EPS Last/This Y

1.61

EPS This/Next Y

-0.08

Price

28

Target Price

28.28

Analyst Recom

2.55

Performance Q

8.15

Upside

-64.5%

Beta

0.29

Ticker: PFE




23 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-22PFE24.840.840.372457428
2026-07-23PFE24.990.830.082479341
2026-07-24PFE24.550.840.542480618
2026-07-27PFE24.670.830.682410320
2026-07-28PFE25.260.830.802438764
2026-07-29PFE25.170.840.702487077
2026-07-30PFE24.910.840.672503902
2026-07-31PFE25.030.840.502526448
2026-08-03PFE25.040.820.892447042
2026-08-04PFE25.40.830.382534473
2026-08-05PFE25.60.820.752567946
2026-08-06PFE26.180.830.912582364
2026-08-07PFE26.750.830.542634155
2026-08-10PFE27.050.831.262521710
2026-08-11PFE26.60.840.592579347
2026-08-12PFE26.310.840.422611845
2026-08-13PFE26.80.840.342631061
2026-08-14PFE26.790.820.532655976
2026-08-17PFE26.860.810.442537860
2026-08-18PFE27.260.810.592567708
2026-08-19PFE28.250.810.442584539
2026-08-20PFE27.810.820.582710399
2026-08-21PFE28.060.820.842745137
DateSymbolLatestP/C OIP/C VolTotal OI
23 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-22PFE24.83-13.08743.72.94
2026-07-23PFE24.99-13.08901.82.94
2026-07-24PFE24.55-12.78538.02.94
2026-07-27PFE24.66-12.79123.92.94
2026-07-28PFE25.25-12.79142.12.94
2026-07-29PFE25.17-12.78749.02.94
2026-07-30PFE24.90-12.78652.12.94
2026-07-31PFE25.03-12.58863.42.94
2026-08-03PFE25.05-12.58817.42.94
2026-08-04PFE25.05-12.58817.42.94
2026-08-05PFE25.79-12.59008.32.95
2026-08-06PFE26.20-12.59021.82.95
2026-08-07PFE26.75-12.511268.82.95
2026-08-13PFE26.80-11.912319.22.97
2026-08-14PFE26.78-11.912051.02.97
2026-08-17PFE26.86-12.812096.02.97
2026-08-18PFE27.26-12.812265.02.98
2026-08-19PFE28.25-12.812584.32.98
2026-08-20PFE27.82-12.811845.22.98
2026-08-21PFE28.00-12.812167.02.98
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-22PFE-0.031.352.87
2026-07-23PFE-0.031.352.87
2026-07-24PFE-0.031.352.87
2026-07-27PFE-0.031.292.88
2026-07-28PFE-0.031.292.88
2026-07-29PFE-0.031.292.88
2026-07-30PFE-0.031.292.88
2026-07-31PFE-0.031.292.88
2026-08-03PFE-0.031.012.88
2026-08-04PFE-0.031.012.88
2026-08-05PFE1.211.012.88
2026-08-06PFE1.151.012.88
2026-08-10PFE1.15-0.442.88
2026-08-11PFE1.15-0.442.88
2026-08-12PFE1.63-0.442.84
2026-08-13PFE1.63-0.442.84
2026-08-14PFE1.63-0.442.84
2026-08-17PFE1.63-0.232.84
2026-08-18PFE1.63-0.232.84
2026-08-19PFE1.63-0.232.84
2026-08-20PFE1.63-0.232.84
2026-08-21PFE2.18-0.232.84
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

0.77

Avg. EPS Est. Current Quarter

0.76

Avg. EPS Est. Next Quarter

0.71

Insider Transactions

2.18

Institutional Transactions

-0.23

Beta

0.29

Average Sales Estimate Current Quarter

15949

Average Sales Estimate Next Quarter

16871

Fair Value

32.91

Quality Score

70

Growth Score

44

Sentiment Score

87

Actual DrawDown %

54.6

Max Drawdown 5-Year %

-59

Target Price

28.28

P/E

37.16

Forward P/E

9.7

PEG

P/S

2.51

P/B

1.88

P/Free Cash Flow

14.56

EPS

0.76

Average EPS Est. Cur. Y​

2.98

EPS Next Y. (Est.)

2.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

6.8

Relative Volume

0.87

Return on Equity vs Sector %

-21.4

Return on Equity vs Industry %

-30.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

12167
PFE Healthcare
$28.07
📉
Swing / Pullback
Buy the dip on strong trends
44 /100
WEAK
Trend
20/20
Pullback
8/25
Volume
4/15
Valuation
9/20
TP/AR
0/10
Options
3/10
RSI
70.2
Range 1M
88.6%
Sup Dist
1.8%
🚀
Momentum Growth
Ride accelerating trends
36 /100
WEAK
Momentum
23/25
Growth
4/30
Estimates
3/20
Inst/Vol
2/15
Options
4/10
EPS Yr
-7.6%
EPS NY
-2.7%
52W%
85.2%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟡 HOLD +22.5% upside
Quality
8/30
Valuation
13/30
Growth
3/25
Stability
3/10
LT Trend
4/5
Upside
+22.5%
Quality
70
MoS
18%
PFE — P/E HistoricalDrug Manufacturers - General
Pfizer, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 75000
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
PFE

Latest News

Caricamento notizie per PFE
stock quote shares PFE – Pfizer Inc. Stock Price stock today
news today PFE – Pfizer Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PFE – Pfizer Inc. yahoo finance google finance
stock history PFE – Pfizer Inc. invest stock market
stock prices PFE premarket after hours
ticker PFE fair value insiders trading